Clinical trials: CTLA4
Health Volunteer
Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects
This is a single-center, randomized, double-blind, does-escalation Phase I Clinical Study that aim to evaluate the tolerability, safety and PK Characteristics of recombinant humanized CTLA-4-FC fusion protein injection in Healthy…
- Trial name
- NCT05256719
- Testing
- Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg, Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg, Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Beijing VDJBio Co., LTD.
Healthy Male Subjects
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
The purpose of this study is to evaluate the pharmacokinetic similarity of AK104 with different manufacturing process in healthy male subjects.
- Trial name
- NCT05559554
- Testing
- AK104 (before the change), AK104 (after the change)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Akeso
Healthy Male Adults Participants
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
This study is to evaluate the pharmacokinetic (PK) similarity of AK104 (an anti-PD-1/CTLA-4 bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male participants.
- Trial name
- NCT07619001
- Testing
- AK104 (New Site), AK104 (Original Site)
- Where
- China
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Akeso
Healthy Male Volunteers
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY® Injection in Healthy Chinese Male Subjects
- Trial name
- NCT06159101
- Testing
- HLX13, CN-sourced ipilimumab, EU-sourced ipilimumab group
- Where
- China
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech